Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.63 |
| ▸ | PGK1 | P00558 | 1/20 | 0.50 |
| ▸ | PGK2 | P07205 | 1/20 | 0.50 |
| ▸ | PGD | P52209 | 3/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.39 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.39 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10709491 | 1.00 | MPI (0.63) | MPIPGK1PGK2PGDAKR1B1 | |
| SCHEMBL28125367 | 1.00 | MPI (0.63) | MPIPGK1PGK2PGDAKR1B1 | |
| SCHEMBL1395698 | 1.00 | MPI (0.63) | MPIPGK1PGK2PGDAKR1B1 | |
| SCHEMBL34088 | 1.00 | MPI (0.63) | MPIPGK1PGK2PGDAKR1B1 | |
| Ammonia Solution, Strong SCHEMBL28280469 | 0.98 | MPI (0.61) | MPIPGK1PGK2PGDAKR1B1 | |
| Phosphoric Acid SCHEMBL17103808 | 0.98 | MPI (0.61) | MPIPGK1PGK2PGDAKR1B1 | |
| Phosphoric Acid SCHEMBL6754811 | 0.98 | MPI (0.61) | MPIPGK1PGK2PGDAKR1B1 | |
| SCHEMBL18341376 | 0.92 | MPI (0.55) | MPIPGK1PGK2PGDAKR1B1 | |
| SCHEMBL10794963 | 0.92 | AKR1B1 (0.56) | MPIPGK1PGK2PGDAKR1B1 | |
| Methoxyamine SCHEMBL1703214 | 0.90 | MPI (0.53) | MPIPGK1PGK2PGDLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121300557-B | Greenhouse crop habitat optimization method, system, equipment and storage medium | NORTHWEST A & F UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| EP-4743568-A1 | INCREASED PRODUCTION OF ACETYL-COENZYME A AND DERIVED PRODUCTS IN YEASTS | DANSTAR FERMENT AG (CH) | 2026-05-20 | — | — | EP | claimed |
| US-20260035705-A1 | ENGINEERED MICROORGANISMS WITH G3P ->3PG ENZYME AND/OR FRUCTOSE-1,6-BISPHOSPHATASE INCLUDING THOSE HAVING SYNTHETIC OR ENHANCED METHYLOTROPHY | AGAIN BIO APS (DK) | 2026-02-05 | — | — | US | claimed |
| US-20250367290-A1 | ENGINEERED STEM CELLS AND USES THEREOF | Umoja Bioharma, Inc. (US) | 2025-12-04 | — | — | US | claimed |
| US-20250250214-A1 | METHOD FOR DEHYDRATION OF ALCOHOL MIXTURES | BRASKEM S.A. (BR) | 2025-08-07 | — | — | US | claimed |
| WO-2025129084-A1 | ENGINEERED INDUCED STEM CELL DERIVED MYELOID CELLS AND METHODS OF DIFFERENTIATING AND USING SAME | UMOJA BIOPHARMA, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| CN-118638664-B | Genetically engineered bacterium for preparing ethanol based on lignocellulose hydrolysis sugar and application thereof | 北京化工大学 | 2025-04-25 | — | — | CN | claimed |
| EP-4536693-A1 | ENGINEERED STEM CELLS AND USES THEREOF | Umoja Biopharma, Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| US-20250041415-A1 | CYTOTOXIC INNATE LYMPHOID CELL AND USES THEREOF | UMOJA BIOPHARMA, INC. (US) | 2025-02-06 | — | — | US | claimed |
| WO-2025015396-A1 | INCREASED PRODUCTION OF ACETYL-COENZYME A AND DERIVED PRODUCTS IN YEASTS | DANSTAR FERMENT AG (CH) | 2025-01-23 | — | — | WO | claimed |
| US-7402710-B2 | Process for producing chiral hydroxyaldehyde compounds | MITSUI CHEMICALS, INC. (JP) | 2008-07-22 | — | — | US | claimed |
| WO-2008008256-A2 | METHODS FOR ENHANCING PRODUCTION OF ISOPRENOID COMPOUNDS BY HOST CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-17 | — | — | WO | claimed |
| US-20070238159-A1 | Production of Isoprenoids | Amyris, Inc. | 2007-10-11 | — | — | US | claimed |
| US-20070196906-A1 | Process For Producing Chiral Hydroxyaldehyde Compounds | MITSUI CHEMICALS, INC. (JP) | 2007-08-23 | — | — | US | claimed |
| EP-1734129-A1 | PROCESS FOR PRODUCTION OF CHIRAL HYDROXYALDEHYDES | Mitsui Chemicals, Inc. (JP) | 2006-12-20 | — | — | EP | claimed |
| EP-1625223-A2 | CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STATIN INTERMEDIATES | Diversa Corporation (US) | 2006-02-15 | — | — | EP | claimed |
| WO-2004027075-A2 | CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STAIN INTERMEDIATES | DIVERSA CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
| EP-1218486-A4 | IMPROVEMENT OF CLAVULANIC ACID PRODUCTION | UNIV JOHNS HOPKINS (US) | 2002-11-04 | — | — | EP | claimed |
| EP-1218486-A1 | IMPROVEMENT OF CLAVULANIC ACID PRODUCTION | The Johns-Hopkins University (US) | 2002-07-03 | — | — | EP | claimed |
| WO-2001019959-A1 | IMPROVEMENT OF CLAVULANIC ACID PRODUCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2001-03-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367290-A1 | ENGINEERED STEM CELLS AND USES THEREOF | IL2RA, IL2, IL15RA | MPI 2275/4885PGK1 3136/4885PGK2 3630/4885 |
| US-20250041415-A1 | CYTOTOXIC INNATE LYMPHOID CELL AND USES THEREOF | IL2RA, IL15RA, IL2 | MPI 2658/4885PGK1 4262/4885PGK2 3446/4885 |
| US-20260035705-A1 | ENGINEERED MICROORGANISMS WITH G3P ->3PG ENZYME AND/OR FRUCTOSE-1,6-BISPHOSPHATASE INCLUDING THOSE HAVING SYNTHETIC OR ENHANCED METHYLOTROPHY | ME1, FBP1, ME3 | MPI 38/4885PGK1 44/4885PGK2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.